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centers. As the availability of LVADs for advanced heart failure has expanded to non-
transplantation mechanical circulatory support centers, concerns have been expressed about
maintaining good outcomes. Demographics and outcomes were evaluated in 276 patients with
advanced heart failure who underwent implantation of LVADs as bridge to transplantation or
destination therapy at 27 open-heart centers. Baseline characteristics, operative mortality,
length of stay, readmission rate, adverse events, quality of life, and survival were analyzed.
The overall 30-day mortality was 3% (8 of 276), and survival rates at 6, 12, and 24 months,
respectively, were 92 – 2%, 88 – 3%, and 84 – 4% for the bridge-to-transplantation group and
81 – 3%, 70 – 5%, and 63 – 6% for the destination therapy group, comparable with results
published by the national InteragencyRegistry forMechanically AssistedCirculatory Support
(INTERMACS). Themedian length of stay for all patients was 21 days. Bleeding was themost
frequent adverse event. Stroke occurred in 4% (bridge to transplantation) and 6% (destination
therapy) of patients. Quality-of-life measures and 6-minute walk distances showed sustained
improvements throughout support. In conclusion, outcomes with LVAD support at open-
heart centers are acceptable and comparable with results from the INTERMACS registry.
With appropriate teams, training, center commitment, and certiﬁcation, LVAD therapy is
being disseminated in a responsible way to open-heart centers.  2015 Elsevier Inc. All
rights reserved. (Am J Cardiol 2015;115:1254e1259)Treatment of advanced-stage heart failure with left
ventricular assist device (LVAD) support provides quality-
of-life and survival beneﬁt in most recipients.1e6 The
development of LVAD technology has been closely asso-
ciated with heart transplantation, while the greatest potential
for expanded use is for destination therapy (DT) in non-
transplantation candidates.7,8 The use of LVADs beyond
heart transplantation centers has been somewhat controver-
sial because of concerns about adequate training, clinical
experience, and the availability of necessary resources.9,10 In
2009, after commercial approval of the HeartMate II LVAD
(Thoratec Corporation, Pleasanton, California) for bridge
to transplantation (BTT), nontransplantation mechanical
circulatory support (MCS) centers began implanting this
device with the support of partnering MCS-transplantation
centers. Today, LVAD implantation for BTT and DT isHealth System, Richmond, Virginia; bHeart Failure
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0.1016/j.amjcard.2015.02.010performed regularly at MCS centers. This report provides
outcome data for patients who underwent LVAD implan-
tation as BTT and DT at nontransplantation MCS centers.
Methods
This retrospective study was conducted using data from
276 patients who underwent implantation of the HeartMate II
LVAD at 27 MCS centers as BTT and DT. Patient data are
presented by indication, BTT (n ¼ 100) or DT (n ¼ 176),
as identiﬁed by the implanting center. Implantation of the
HeartMate II LVAD at the MCS centers began in April 2009,
after commercial approval of the device as BTT. Before
starting LVAD implantation at the MCS centers, agreements
were established with partnering MCS-transplantation
centers to ensure that heart transplantation candidates were
evaluated and listed according to the guidelines of the
United Network for Organ Sharing. The partnering MCS-
transplantation centers provided workup and care protocols
speciﬁc to their programs and served as resources for infor-
mation on case management as needed.
All patients were enrolled in the Interagency Registry for
Mechanically Assisted Circulatory Support (INTERMACS)
and gave informed consent that was approved by the insti-
tutional review board at each of the participating centers.
The time frame for the data used in this study extends from
the date of the ﬁrst HeartMate II implantation as BTT at an
MCS center (April 2009) to September 30, 2012. The ﬁrst
implantation for the DT indication occurred in Januarywww.ajconline.org
Table 1
Baseline characteristics
Variable Bridge-to-Transplant (n ¼ 100) Destination Therapy (n ¼ 176) All (N ¼ 276)
Males 81 (81%) 145 (82%) 226 (82%)
Age (Years)
59 62 (62%) 49 (28%) 111 (40%)
60e69 32 (32%) 65 (37%) 97 (35%)
70 6 (6%) 62 (35%) 68 (25%)
Heart Failure Etiology
Ischemic cardiomyopathy 43 (43%) 103 (59%) 146 (53%)
Idiopathic cardiomyopathy 34 (34%) 48 (27%) 82 (30%)
Other etiology 24 (24%) 25 (14%) 49 (18%)
INTERMACS Proﬁle
1: Critical cardiogenic shock 7 (7%) 17 (10%) 24 (9%)
2: Progressive decline 32 (32%) 52 (30%) 84 (30%)
3: Stable but inotrope dependent 44 (44%) 72 (41%) 116 (42%)
4e7: Non-inotrope dependent 17 (17%) 35 (20%) 52 (19%)
Hemodynamics
Heart rate (bpm) 85.8 17.7 84.9 15.0 85.2 16.1
Mean blood pressure (mmHg) 78.7 10.6 76.7 11.1 77.4 11.0
Pulmonary wedge pressure (mmHg) 22.9 10.4 22.9 8.1 22.9 9.0
Right atrial pressure (mmHg) 13.2 8.4 13.8 7.7 13.6 7.9
Cardiac index (L/min/m2) 2.14 0.63 2.12 0.67 2.12 0.65
Laboratory Data
Blood urea nitrogen (mg/L) 23.8 13.4 29.4 15.0 27.4 14.6
Creatinine (mg/dL) 1.25 0.47 1.46 0.72 1.39 0.65
Total bilirubin (mg/dL) 1.34 1.14 1.40 1.61 1.38 1.46
Serum glutamic oxaloacetic transaminase (u/L) 39.6 30.5 49.0 96.3 45.6 79.0
Serum glutamic pyruvic transaminase (u/L) 45.8 49.8 50.5 87.3 48.8 75.7
International normalized ratio 1.36 0.46 1.29 0.23 1.31 0.33
Table 2
Survival rate and number of patients alive (n) by INTERMACS proﬁle
Proﬁle Bridge to Transplant Destination Therapy
6-Month
(n ¼ 59)
12-Month
(n ¼ 36)
6-Month
(n ¼ 86)
12-Month
(n ¼ 37)
1 100%(2) 100% (1) 63.4 12.0% (7) NA
2 96.9 3.1% (20) 91.8 5.8% (10) 82.4 5.7% (28) 64.3 8.5% (16)
3 92.7 4.1% (28) 88.0 6.0% (19) 81.5 5.1% (37) 76.4 5.9% (13)
4e7 100% (9) 100% (6) 87.9 6.7% (14) 72.6 11.5% (8)
Patients were censored for transplant and death, or support was ongoing for < 12 months.
NA ¼ not applicable.
Heart Failure/LVAD Outcomes at Nontransplantation Centers 12552012. Each participating center entered data into the registry
according to instructions in the INTERMACS manual of
operations. Data obtained from INTERMACS for this study
were the subset of patients who underwent implantation at
the MCS centers.
Baseline characteristics, operative mortality, major
adverse event rates, length of stay in the hospital, rehospi-
talization rate, physical status, quality-of-life measures, and
survival to 2 years were analyzed. Data for 30-day, 6-month,
and 12-month survival that were grouped by INTERMACS
proﬁles (proﬁles 1, 2, 3, and 4 to 7) were assessed for dif-
ferences based on severity of illness. Reported adverse
events are deﬁned by the INTERMACS protocol. Physical
status evaluated with the 6-minute walk test and quality-
of-life measures evaluated with the EuroQol EQ-5D visualanalog scale and total quality-of-life scores at baseline, 3, 6,
and 12 months were analyzed. The total quality-of-life
score is a composite score evaluating anxieties, mobility,
pain, and self-care.
Continuous data are reported as mean  SD, and discrete
variables are reported as percentages. Survival analysis was
performed using the Kaplan-Meier method with censoring
when LVAD support was stopped for heart transplantation or
when recovery enabled device removal. Adverse events are
given as the total number of events and the event rate (number
of events divided by total patient-years). Statistical analyses
were performed using SAS version 9.2 (SAS Institute Inc.,
Cary, North Carolina). Data are presented in 2 groups ac-
cording to indication for LVAD support (BTT or DT), but
statistical comparisons between the groupswere not performed.
Table 3
The number of implants for bridge to transplant, destination therapy and
total number of implants by MCS center
SMCS Center Bridge to
Transplant
Destination
Therapy
Total
Abington Memorial 0 1 1
Albert Einstein 1 0 1
Banner Good Samaritan 0 2 2
Hackensack University Med Ctr. 3 0 3
Lancaster General 1 11 12
Lankenau Hospital 0 4 4
Morristown Memorial Hospital 6 14 20
MultiCare Health System 0 6 6
New York University Med Ctr. 6 6 12
OSF St Francis Med Ctr. 2 1 3
Penn Presbyterian Med Ctr. 1 7 8
Piedmont Hospital 14 41 55
Providence St Vincent Med Ctr. 2 9 11
Scott & White Hospital 4 8 12
Scripps Memorial Hospital 1 0 1
Spectrum health Hospitals 7 21 28
St Mary’s Hospital 17 8 25
Stony Brook University Med Ctr. 7 2 9
The Heart Hospital Baylor Plano 0 3 3
The Christ Hospital 11 5 16
The Indiana Heart Hospital 1 1 2
The Med Ctr. of Central Georgia 0 3 3
University of Toledo 1 4 5
UC Health University Hospital 0 8 8
UC Davis Med Ctr. 1 2 3
UC San Diego Med Ctr. 1 1 2
Weill Cornell Med Ctr. 16 8 24
Figure 1. Kaplan-Meier survival curve for the BTT (top) and DT (bottom)
groups.
Table 4
Reasons for hospital readmission for the destination therapy cohort
Reason Number of readmissions
Cardiac arrhythmia 6
Bleeding 13
Hematoma 1
Hemolysis 1
Infection 9
Gastrointestinal disorder 6
Gastrointestinal bleeding 11
Planned procedure 3
Device malfunction 1
Suspected device thrombosis 1
Neurologic event 6
Psychiatric event 1
Renal dysfunction 1
Wound dehiscence 2
Other not speciﬁed 24
Multiple events 22
1256 The American Journal of Cardiology (www.ajconline.org)Results
The baseline characteristics for patients who underwent
implantation of the HeartMate II as BTT (n ¼ 100), as DT
(n ¼ 176), and the 2 groups combined (n ¼ 276) are listed
in Table 1. The 2 groups were composed predominantly of
men, and the age distribution (ranges deﬁned by INTER-
MACS) was consistent with the indication for support (i.e.,
35% of patients were >70 years of age in the DT group, and
only 6% were >70 years of age in the BTT group). Most
BTT patients (67%) were 50 to 69 years of age, and those in
the DT group were predominately >60 years of age (72%).
The severity of illness deﬁned on the basis of INTERMACS
proﬁle was similar for the 2 groups. Patients with critical
cardiogenic shock (INTERMACS proﬁle 1) represented the
smallest proportion in both groups. Hemodynamic and
laboratory parameters for the 2 groups were representative
of advanced-stage heart failure.
The average duration of support for all MCS center patients
(n¼ 276) was 8.3 7.2 months (median 6.2, range 0 to 36.4)
andwas 9.6 7.6months for BTT (maximum 36.4) and 7.6
6.8 months for DT (maximum 31.2). Shorter follow-up of DT
patients occurred because centers only more recently started
DT programs. The cumulative follow-up duration was 81.0
patient-years for BTT and 109.8 patient-years for DT.At the time of the analysis cutoff date (December 2012),
20 of the BTT patients (20%) and 7 of the DT patients (4%)
had undergone heart transplantation. Death during support
occurred in 8 of 100 BTT patients (8%) and in 40 of 176 DT
patients (23%). The number of patients remaining on LVAD
support was 195 of 276 (71%): 68 of 100 BTT patients
(68%) and 127 of 176 DT patients (72%). One patient had
Table 5
Adverse-event rates for the bridge to transplant and destination therapy groups
Bridge-to-Transplant
(81.0 pt-years)
Destination Therapy
(109.8 pt-years)
Adverse Events N Events, n Events/
pt-year
N Events, n Events/
pt-year
Bleeding 18 (18%) 78 0.96 75 (43%) 161 1.47
Gastrointestinal bleeding 8 (8%) 56 0.69 34 (19%) 74 0.67
Bleeding requiring surgery 5 (5%) 5 0.06 25 (14%) 26 0.24
Cardiac arrhythmias 16 (16%) 20 0.25 24 (14%) 39 0.36
Device infection 13 (13%) 15 0.18 13 (7%) 15 0.14
Stroke 4 (4%) 5 0.06 11 (6%) 12 0.11
Hemorrhagic stroke 1 (1%) 1 0.01 4 (2%) 4 0.04
Ischemic stroke 3 (3%) 4 0.05 4 (2%) 5 0.05
Unknown type 0 (0%) 0 0.00 3 (2%) 3 0.03
Right-heart failure 7 (7%) 8 0.10 21 (12%) 28 0.26
Heart Failure/LVAD Outcomes at Nontransplantation Centers 1257the device explanted after myocardial recovery, 4 patients
underwent device exchange because of thrombosis, and 2
devices were exchanged for unspeciﬁed device malfunc-
tions. The overall 30-day mortality was 3% (8 of 276), with
2 deaths in the BTT group that were INTERMACS proﬁle 2
and proﬁle 3, respectively, and 6 deaths in the DT group that
were INTERMACS proﬁle 1 (n ¼ 3) or proﬁle 2 (n ¼ 3).
The survival rates by INTERMACS proﬁle are given in
Table 2. The Kaplan-Meier survival rates (Figure 1) at 6, 12,
and 24 months, respectively, for the BTT group were 92 
2%, 88  3%, and 84  4%; for the DT group,
the respective survival rates were 81  3%, 70  5%, and
63  6%.
The 276 patients underwent implantation of the Heart-
Mate II at 27 MCS centers with an average of 10.3  11.7
(range 1 to 55) implantations per center (Table 3). The
survival rates at 1, 6, and 12 months at the centers with 20
implants (n ¼ 127) were 96.8  1.6%, 89.8  3.0%, and
78.2  5.2%, respectively, and at centers with >20
implantations, the rates were 98.0  2.0%, 85.6  3.1%,
and 80.4  3.9%, respectively (p ¼ 0.702).
After LVAD implantation, the median length of stay in
the hospital was 21 days for all MCS center patients, and it
was 6 days longer for DT patients (22.5 days) than for BTT
patients (16.5 days). The percentages of patients discharged
after LVAD implantation were 92% for BTT patients, 90%
for DT patients, and 91% for all patients. The hospital
readmission rate was 1.48 events per patient-year (1.10 for
BTT, 1.77 for DT). The reasons for readmission in the DT
cohort are listed in Table 4.
The most common adverse event was bleeding and is
presented as either of gastrointestinal origin or postoperative
bleeding requiring reoperation (Table 5). Cardiac arrhythmia
was also common, followed by device infection and right-
sided cardiac failure. The overall adverse event rates were
higher for the DT group.
Both BTT and DT patients had improved quality of life at
the 3-month time point, with the improvements maintained
to 12 months (Figure 2). At 3 months after implantation, the
mean values on the EuroQoL visual analog scale had
improved by 31.7 points for the BTT group and 34.9 points
for the DT group (Figure 2). In the same time frame, the totalmean composite quality-of-life score decreased (indicating
improved quality of life) by 1.94 points for BTT patients and
1.63 points for DT patients (Figure 2). There was also marked
improvement in 6-minute walk distances from preimplanta-
tion to 3 months, with walk distances maintained by the 2
groups of patients through 12 months (Figure 2). The number
of patients participating in quality-of-life tests varied because
of severity of illness, lower limb problems or inability to
complete the test, scheduling issues, and choice given the
voluntary participation by centers.
Discussion
In recent years, considerable progress has been made to
improve the outcomes of patients who undergo LVAD
support as BTT and DT. The 1-year survival rate for the
BTT indication has progressed from 68% in the early phase
of the clinical trial1 to 85% in post-trial studies.4,5 Similarly,
for patients supported for the DT indication, survival has
increased from 68% early in the clinical trial3 to 75% in the
INTERMACS registry.11 In this study at MCS centers, the
1- and 2-year survival rates, respectively, were 92% and
88% for BTT patients and 70% and 63% for DT patients
(Table 6). These results are comparable with those from the
INTERMACS registry as a whole and indicate that good
outcomes can be achieved in patients who undergo LVAD
implantation at MCS centers.
The results of this study demonstrate that patients with
advanced-stage heart failure who undergo implantation of
LVADs have improved quality of life and survive for dura-
tions seen in like populations. Similar to the improvements
observed in the quality-of-life measures, physical functioning
was enhanced, as demonstrated by the changes in the
6-minute walk distances. Adverse event rates appear to be
within acceptable ranges, as they are not greatly different from
reports of the large clinical trials.1e6 The observed hospital-
ization time and duration of LVAD support follow the trends
of large populations of LVAD-supported patients.11
This observational study was intended as a benchmark
for assessing the outcomes of LVAD therapy at centers
without transplantation services or histories of MCS
programs. A legitimate concern has been that a fast-paced
Figure 2. EuroQol visual analog scale (A) and the total composite quality-
of-life (QOL) score (B) show improvements in QOL over time after LVAD
implantation in BTT and DT patients. There was marked improvement in 6-
minute walk distance (C) in the 2 groups.
Table 6
Outcomes from open heart centers in the current study compared to
outcomes from the HeartMate II clinical trial and INTERMACS registry
No. of
study
Patients
1-year
Survival
2-year
Survival
Bridge-to-Transplant (BTT)
Open Heart Centers 100 92% 88%
BTT Clinical Trial (Miller et al.,
NEJM 2007)1
133 68%
BTT Clinical Trial (Pagani et al.,
JACC 2009)2
281 74%
BTT Post-Approval Study (Starling,
JACC 2011)5
169 85%
BTT Post Trial (John et al., Ann Thor
Surg 2011)4
1496 85%
INTERMACS Registry (Kirklin et al.,
JHLT 2014)11
5886 83% 74%
Destination Therapy (DT)
Open Heart Centers 176 70% 63%
DT Clinical Trial (Slaughter et al.,
NEJM 2009) 3
133 68% 58%
DT Clinical Trial (Park et al., CIRC
HF 2012) 6
281 73% 63%
INTERMACS Registry (Kirklin et al.,
JHLT 2014)11
3373 75% 64%
1258 The American Journal of Cardiology (www.ajconline.org)expansion of LVAD implantation after commercial approval
would have a negative effect on patient outcomes.10 Sufﬁ-
cient professional resources dedicated to advance heart
failure care at all types of centers are necessary to achieve
positive outcomes in the very challenging heart failure
population.12 The directors of the LVAD programs at the
MCS centers—cardiac surgeons and cardiologists—were
previously trained at academic medical centers at which
heart transplantation and MCS were included as part of the
training program. In addition, for DT certiﬁcation by theCenters for Medicare and Medicaid Services, an MCS center
cardiac surgeon is required to complete a minimum of 10
LVAD implantations within a 36-month period. All of the
MCS centers have either completed Centers for Medicare
and Medicaid Services DT certiﬁcation or are in the process
of doing so. Dedicated LVAD coordinators at the MCS
centers play a crucial role in the overall management of
cases; other contributing hospital resources, such as
biomedical engineering, social services, perfusion, and
administration, are necessary for the complete care of
LVAD patients. Because patients with heart failure with
LVAD support are susceptible to other organ dysfunction,
medical specialists in pulmonology, renal disease,
neurology, and infectious disease and hematology can
provide important contributions to the program. In addition
to these in-house resources, communication with a collab-
orating transplantation center is an essential component in
MCS center patient outcome. All MCS centers have
agreements with transplantation centers to ensure appro-
priate workup, listing, and eventual transplantation for those
patients who undergo support as BTT.
Most of the heart failure population in the United States
has limited access to LVAD therapy. Patients with heart
failure are distributed throughout the United States, and
care is provided by many medical centers in a variety of
communities. The limited access to LVAD therapy is the
result of geographic constraints and the general deﬁciency
of referral networks. Currently, the number and locations of
the most experienced transplantation centers that provide
LVAD therapy are not adequate to serve the large popula-
tion of patients with heart failure.13 Expansion of LVAD
therapy to qualiﬁed nontransplantation medical centers is
necessary to more effectively treat the vast number of pa-
tients with heart failure.
Heart Failure/LVAD Outcomes at Nontransplantation Centers 1259A limitation of this study is that patients at the MCS
centers may not be perfectly matched to those from the
clinical trials or to other patients in the INTERMACS reg-
istry; an analysis of that is beyond the scope of this project.
The retrospective analysis of registry data may have vari-
ability in the completeness and accuracy of reporting. There
also may be a delay in complete entry of all individual
patient data, from implantation to outcome, and auditing and
adjudication of data is not as thorough as in U.S. Food and
Drug Administrationeapproved clinical trials.Acknowledgments: The authors acknowledge Mary
McGarigle, Jerry Heatley, and Tim Myers from Thoratec
Corporation for their assistance with statistical analysis and
technical writing.
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